2025-08-18
Anocca has secured SEK 440 million to advance its VIDAR-1 clinical trial, a pioneering gene-edited TCR-T therapy targeting pancreatic cancer.
Anocca AB has raised approximately SEK 440 million (USD 46 million) to progress its clinical programme for VIDAR-1, a gene-edited TCR-T therapy targeting pancreatic cancer.
The financing round was led by Mellby Gård with continued support from AMF, Ramsbury, and other existing shareholders. Several new investors also joined the round. The capital will be used to advance VIDAR-1 through early-stage clinical development and strengthen Anocca’s wider preclinical pipeline.
VIDAR-1 is the first non-viral gene-edited TCR-T cell therapy to enter clinical testing in Europe. Recruitment is now open for Phase I of the multi-centre trial, taking place across university hospitals in Sweden, Denmark, Germany, and the Netherlands.
The trial is designed as a multi-product umbrella study targeting KRAS mutations in pancreatic ductal adenocarcinoma (PDAC). Up to 20 patients per product are expected to be enrolled in the phase I/II studies.
Mutations in the KRAS gene drive disease progression in pancreatic, lung, and colorectal cancers. In pancreatic cancer, KRAS mutations are present in around 90% of cases. Despite medical advances, the five-year survival rate for patients with PDAC remains below 10%.
By focusing on gene-edited TCR-T therapies, Anocca aims to provide innovative treatment options for patients with limited alternatives today.
The VIDAR-1 trial builds on Anocca’s proprietary platform for T-cell receptor engineering and in-house cell therapy manufacturing in Södertälje, Sweden. With this financing, the company strengthens its ability to translate discoveries into clinical benefit for patients.
More information about the clinical trial can be found on the EU Clinical Trials Register.